Circassia is a speciality pharmaceutical company focused on respiratory disease.
Their commercial organization promotes their innovative asthma management products directly to specialist physicians in several key markets, and they market the chronic obstructive pulmonary disease (COPD) products Tudorza® and Duaklir® in the United States.
Recently, they significantly expanded the commercial platform in China, launching their own direct sales team. They are working to expand our portfolio further through in-licensing, partnering or acquisition, and recently they acquired the commercial rights to the ventilator-compatible nitric oxide product LungFit PH* in the US and China.
Circassia was established in 2006, and in March 2014 they completed an initial public offering on the London Stock Exchange. In June 2015, they completed the acquisition of NIOX® as part of their strategy to independently commercialize their products and broaden our portfolio, and in April 2017 they established their commercial collaboration with AstraZeneca in the United States for COPD products Tudorza® and Duaklir®.
In January 2019, they acquired the commercial rights to LungFit PH in the US and China, and in February 2019 they completed the move of the Company’s shares to AIM where they are quoted under CIR.